ReviewOncology letters2025
Discoidin domain receptor tyrosine kinase 2: A new perspective on microenvironment remodeling and targeted therapy of solid tumors (Review).
Review in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DDR2-COL11A1 Transcriptional Coupling as a Candidate Therapeutic Target in Colorectal Cancer: Integrative Transcriptomic and Deep Learning Validation.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is one of the major areas on which global medical research and treatment development are currently focused. There has been an increasing incidence of several types of cancer, such as breast cancer, pancreatic cancer, uterine cancer, prostate cancer, liver cancer, kidney cancer, human papillomavirus-associated oral cancer and melanoma. Advancements in biomedical research have expanded treatment options for numerous cancers; however, an ideal or definitive cure remains elusive. Therefore, identifying novel targets for cancer treatment has become a major area of research in biomedicine. Due to its involvement in several human diseases and tumor progression, discoidin domain receptor tyrosine kinase 2 (DDR2) has attracted considerable attention. The present review synthesizes findings from previous studies and highlights the recent advances in DDR2 research, assesses its role across different types of tumors and evaluates its emerging significance in multiple biomedical fields.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.